Literature DB >> 10758842

[Thiamine treatment in psychiatry and neurology].

D Hinze-Selch1, M M Weber, U Zimmermann, T Pollmächer.   

Abstract

Every physician knows that alcohol dependence, alcohol withdrawal and Wernicke-Korsakow-syndrome require substitution with thiamine, in acute stages even parenterally. This would be trivial if there was not the widespread fear of anaphylactic, even lethal reactions to parenteral thiamine application. The present article reviews the literature published on thiamine since 1936, when the first synthetic, parenteral thiamine preparation became available, and, on this basis, tries to give practical advice and therapeutic regimens for the treatment of thiamine deficiency states. Controlled clinical studies on indications and differential thiamine therapy have not been published. From the data that are available, the following conclusions can be drawn: 1) Acute mortality of Wernicke-Korsakow-syndrome is about 20%. 2) Oral thiamine is safe. 3) The risk for an anaphylactic shock due to parenteral thiamine administration is below 1 to 100,000. 4) Not only alcohol but any condition with either increased metabolic need (pregnancy, consuming diseases) or deficient nutrition (including eating disorders) can lead to thiamine deficiency. Therefore, we suggest: 1) Oral thiamine substitution with at least 50 mg per day and supply of a sufficient and complete diet should be given to any person that might be at risk for thiamine deficiency. 2) Any patient suspicious for acute thiamine deficiency needs to be treated under inpatient conditions and there needs to receive 50 to 100 mg thiamine intravenously 3 to 4 times a day. 3) General practitioners, psychiatrists and neurologists should take care of the oral supplementation of thiamine, sufficient nutrition, and they are the physicians to diagnose early stages of thiamine deficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758842     DOI: 10.1055/s-2000-11622

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  7 in total

1.  Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages.

Authors:  Mohammad Shoeb; Kota V Ramana
Journal:  Free Radic Biol Med       Date:  2011-10-24       Impact factor: 7.376

2.  Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages.

Authors:  Umesh C S Yadav; Nilesh M Kalariya; Satish K Srivastava; Kota V Ramana
Journal:  Free Radic Biol Med       Date:  2010-02-26       Impact factor: 7.376

3.  Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial.

Authors:  Ali Ghaleiha; Hassan Davari; Leila Jahangard; Mohammad Haghighi; Mohammad Ahmadpanah; Mohammad Ali Seifrabie; Hafez Bajoghli; Edith Holsboer-Trachsler; Serge Brand
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-03-16       Impact factor: 5.270

Review 4.  [Nutrition and dietary supplements in psychiatric diseases].

Authors:  H Himmerich; F Erbguth
Journal:  Nervenarzt       Date:  2014-12       Impact factor: 1.214

5.  Transketolase and vitamin B1 influence on ROS-dependent neutrophil extracellular traps (NETs) formation.

Authors:  Donporn Riyapa; Darawan Rinchai; Veerachat Muangsombut; Chayanin Wuttinontananchai; Mohammed Toufiq; Damien Chaussabel; Manabu Ato; Jenefer M Blackwell; Sunee Korbsrisate
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

6.  [Diagnostic work-up and treatment of acute psycho-organic syndrome].

Authors:  C Thomas; M Driessen; V Arolt
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

7.  The Impact of 6-month Micronutrient Supplementation on Viral, Immunological, and Mental Health Profile of a Cohort of Highly Active Antiretroviral Therapy-Naive HIV-Positive Patients in Northern Nigeria.

Authors:  Victor Obiajulu Olisah; Tajudeen Abiola; Christopher I Okpataku; Reginald O Obiako; Ishaq A Audu; Bashir A Yakasai
Journal:  Niger Med J       Date:  2019 May-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.